Deutsche Bank Raises Price Target on Auxilium Pharmaceuticals (AUXL) to $22 After Q4

Deutsche Bank boosted its price target on Buy-rated Auxilium Pharmaceuticals (NASDAQ: AUXL) from $21 to $22 following Q4 results.

The firm comments, "Our Buy investment rating on Auxilium is predicated on the still significant commercial opportunity for Xiaflex, coupled with a solid growth outlook for Testim. We believe that Xiaflex, the company’s flagship, non-surgical treatment, could still have peak global sales potential in several indications of $400M+ despite its slow start. Hence, we continue to rate Auxilium shares Buy post the Q4 results."

For an analyst ratings summary and ratings history on Auxilium Pharmaceuticals click here. For more ratings news on Auxilium Pharmaceuticals click here.

Shares of Auxilium Pharmaceuticals closed at $19.48 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• GMR Airports Infrastructure (GMRI:IN) PT Raised to INR99 at ICICI Securities
• Apollo Hospitals (APLH:IN) PT Raised to INR8,500 at ICICI Securities